Quicksilver: a study to assess the safety of a new MRI approach to pre-operatively stage rectal cancer and guide treatment

Conditions

Rectal cancer Cancer

Kennedy ED, Simunovic M, Schmocker S, Pooni A, Brown CJ, MacLean AR, Liberman AS, Drolet S, Neumann K, Stotland P, Cho C, Kopek N, Burkes R, Jhaveri K, Pond GR, Kirsch R, Baxter NN, Rectal Cancer Alliance of Canada .

2026-06-17

10.1245/s10434-026-19991-6

Safety and Feasibility of Using Magnetic Resonance Imaging Criteria to Identify Patients With “Good Prognosis” Rectal Cancer Eligible for Primary Surgery

Erin Kennedy, Marko Šimunović, Kartik Jhaveri, Richard Kirsch, Jim Brierley et al. (38 authors)

JAMA Oncology2019-04-12107 citations

10.1001/jamaoncol.2019.0186

QuickSilver: A Phase II Study Using Magnetic Resonance Imaging Criteria to Identify “Good Prognosis” Rectal Cancer Patients Eligible for Primary Surgery

Rectal Cancer Alliance Of Canada (RCAC)

JMIR Research Protocols2015-04-147 citations

10.2196/resprot.4151

Interventions

Participants (i.e., rectal cancer patients) in this study will receive the exact same tests and surgery that they would receive if they were not participating in this study. However, instead of using

Eligibility

Sex/Gender

All

Age

18 Years to 110 Years

Inclusion criteria

Inclusion criteria: 1. Diagnosis of rectal cancer (0-15 cm) from the anal verge on endoscopy and/or proximal extent of tumour at or below the sacral promontory on CT or MRI 2. 18 years or older 3. Able to provide written consent

Exclusion criteria

Exclusion criteria: 1. Planned abdomino-perineal resection (APR) based on pre-treatment assessment 2. Planned local excision based on pre-treatment assessment 3. Suspicious extramesorectal lymph nodes on MRI 4. Unable to undergo MRI due to claustrophobia, metal fragments, implanted metal devices or contrast allergy 5. Metastatic disease (including extramesorectal lymph nodes, carcinomatosis, liver, lung) 6. Pregnancy 7. Inflammatory bowel disease 8. Previous pelvic radiation 9. More than one primary tumour

Design outcomes

Primary

Measure	Time frame
The primary outcome for the study will be the safety of this new MRI approach in terms of positive circumferential resection margin (CRM) in the pathological specimen. The positive CRM rate is a well-established and accepted surrogate measure of local recurrence and the new MRI criteria will be considered safe if a positive CRM rate of less than 5% is achieved.	—

Countries

Canada

Outcome results

None listed